Tree Nut Allergy: Cross-Reactivity Clusters, Component Testing, and Managing Risk

Not automatically — the answer depends on which nut you are allergic to, which protein class is positive on component testing, and what your cross-reactivity cluster is. If you are cashew-allergic, you must also avoid pistachio (75–98% co-allergy) — but you may be able to eat walnuts and almonds after individual testing. If you are walnut-allergic, you must also avoid pecan — but cashew and hazelnut may be safe after testing. If you have hazelnut allergy driven only by Cor a 1 (birch PR-10), roasted hazelnuts may be safe while raw ones trigger OAS. The modern goal is precise, cluster-based avoidance — not blanket elimination of all tree nuts, which imposes unnecessary dietary restriction. Ask your allergist for component testing to clarify your specific risk profile.

Cashew and pistachio are both members of the Anacardiaceae plant family, and their primary kernel storage proteins share very high sequence homology: Pis v 1 (pistachio 2S albumin) is approximately 70% identical to Ana o 3 (cashew 2S albumin); Pis v 3 (pistachio vicilin) is approximately 78% identical to Ana o 1 (cashew vicilin); Pis v 2 is approximately 80% identical to Ana o 2. At these homology levels, IgE antibodies produced against cashew proteins readily crosslink pistachio proteins and trigger reactions — and vice versa. The result is a 75–98% co-allergy rate in cashew-allergic children, confirmed in NUTCRACKER and IDEAL study populations. In practical terms, cashew and pistachio allergy are the same diagnosis requiring the same management.

Walnut and pecan are both Juglandaceae — the same botanical family — and their kernel storage proteins are structurally similar. Jug r 1 (walnut 2S albumin) and Car i 1 (pecan 2S albumin) share meaningful sequence homology, as do the vicilin and legumin classes across the two species. Clinical studies and patient registries consistently show very high co-reactivity between walnut and pecan — patients confirmed allergic to one Juglandaceae nut are typically counseled to avoid both. The practical implication: if you have confirmed walnut allergy, pecan pie at Thanksgiving poses the same anaphylaxis risk as walnuts in a salad — avoid both systematically.

No — peanut (Arachis hypogaea) is botanically a legume in the Fabaceae family, the same plant family as soybeans, lentils, and chickpeas. It grows underground as a root legume, not on a tree. However, approximately 30% of children with tree nut allergy also have peanut allergy — a clinically significant co-allergy that occurs through independent sensitization rather than direct protein cross-reactivity. The practical consequence is that any child diagnosed with tree nut allergy should be evaluated for peanut allergy, and vice versa. Despite the botanical distinction, peanut and tree nut allergies are managed similarly — strict avoidance, epinephrine auto-injector — and often co-exist in the same patient.

Coconut (Cocos nucifera) is botanically a drupe — a fruit with a fibrous husk and a hard pit containing the seed — not a true tree nut in the botanical sense. However, the FDA classifies coconut as a tree nut for food labeling purposes, so it appears on tree nut allergen labels. Coconut allergy is relatively rare and distinct from the common tree nut allergies — there is minimal cross-reactivity between coconut and cashew, walnut, or hazelnut allergens. Most tree-nut-allergic patients can safely consume coconut after individual testing, but this should be confirmed with an allergist. Do not assume coconut safety or restriction without a formal evaluation specific to your sensitization profile.

Component-resolved diagnostics (CRD) for tree nuts is a type of allergy blood test that measures IgE to specific individual proteins within each nut — rather than to the whole nut extract. The clinically critical components are the 2S albumins (Ana o 3 for cashew, Jug r 1 for walnut, Cor a 14 for hazelnut, Pis v 1 for pistachio, Ber e 1 for Brazil nut) — which are heat-stable storage proteins that predict severe systemic reaction risk. A patient with high Ana o 3 IgE has confirmed anaphylaxis-risk cashew allergy. A patient whose hazelnut IgE is driven only by Cor a 1 (a birch PR-10 cross-reactive protein) has mild OAS from birch sensitization, and roasted hazelnuts may be safe for them. CRD is increasingly the standard for guiding avoidance counseling and epinephrine prescribing decisions in tree nut allergy — ask your allergist specifically about component testing.

Rarely — tree nut allergy resolves spontaneously in fewer than 10% of patients, compared to much higher resolution rates for milk allergy (approximately 80%) and egg allergy (approximately 70%) in childhood. Most adults with tree nut allergy diagnosed in childhood continue to require avoidance indefinitely. Periodic reassessment by a board-certified allergist — including repeat IgE testing every 1–3 years — can identify the rare patient in whom IgE levels have declined significantly and an oral food challenge is warranted. Do not attempt to informally re-introduce tree nuts at home without allergist supervision — even apparent tolerance can mask ongoing sensitization that may produce severe reactions with larger doses.

As of June 2026, no FDA-approved immunotherapy exists for any tree nut. Palforzia — the only FDA-approved food immunotherapy product — is for peanut allergy only. Sublingual immunotherapy (SLIT) and allergy shots (SCIT) are not appropriate for food allergens. Oral immunotherapy (OIT) is the investigational approach — academic allergy centers have active research programs for cashew, walnut, hazelnut, and pistachio OIT, with some participants achieving sustained unresponsiveness. The science is advancing, and tree nut OIT products may reach FDA approval in the coming years. If you are interested in OIT research, ask your allergist about referral to an academic food allergy center with an active OIT program.

Ana o 3 is the primary allergen in cashew nut — a 2S albumin storage protein that is heat-stable (survives roasting) and is the strongest single marker for severe cashew allergy and anaphylaxis risk. A positive Ana o 3 result on component-resolved IgE testing confirms that you have IgE-mediated sensitization to a heat-stable cashew protein, meaning reactions can occur with both raw and roasted cashew. Because Ana o 3 shares approximately 70% sequence homology with pistachio's Pis v 1, a high Ana o 3 also strongly predicts pistachio co-allergy. If your Ana o 3 result is positive, you should also test Pis v 1 for pistachio, carry an epinephrine auto-injector, and avoid both Anacardiaceae family members.

It depends entirely on the protein class driving your sensitization. For patients sensitized to 2S albumins (Ana o 3, Jug r 1, Cor a 14, Pis v 1, Ber e 1) — the anaphylaxis-risk proteins — roasted nuts are NOT safer than raw. These heat-stable proteins survive commercial roasting temperatures and retain their IgE-binding capacity. For patients sensitized to PR-10 proteins only (Cor a 1 for hazelnut, Pru du 1 for almond, from birch sensitization) — the mild OAS proteins — roasted and cooked forms ARE typically safer because PR-10 proteins are heat-labile and denature with cooking. This is the component testing distinction that matters most for practical dietary guidance. Without component testing, you cannot know which category applies to you — which is why a 'raw vs. roasted' rule alone is insufficient guidance.

Hazelnut allergy has two distinct mechanisms that produce dramatically different symptom profiles. The milder pattern is PR-10 OAS: hazelnut Cor a 1 is a birch cross-reactive protein that causes oral tingling and lip swelling within minutes of eating raw hazelnuts — but symptoms stay in the mouth, resolve spontaneously, and are eliminated by cooking, because Cor a 1 is heat-labile. This is common in birch-sensitized patients in the northern US and Europe. The more severe pattern is primary hazelnut allergy driven by heat-stable storage proteins: Cor a 9 (legumin) and Cor a 14 (2S albumin) — these survive roasting and cause systemic reactions including urticaria, angioedema, bronchospasm, and anaphylaxis. Component testing (Cor a 1 vs. Cor a 9/14) definitively distinguishes the two patterns and drives all management decisions — epinephrine prescription and strict avoidance for Cor a 9/14-positive patients; cooking guidance and no epinephrine for Cor a 1-only patients.